On the influence of apomorphine on the toxicity of adrenalin and phenamine

  • M. L. Belen'kii
  • M. A. Vitolinya
  • R. O. Vitolinya


Experiments on albino mice were used to determine the average lethal, doses of apomorphine, adrenalin, phenamine, and mixtures of apomorphine with adrenalin (1∶3 and 3∶1) and apomorphine with phenamine (1∶3 and 3∶1). The obtained values of average lethal doses for the mixtures were compared with those calculated according to these formulas: (1/LD50M)=(Pa/LD50a)+(Pb/LD50b), where LD50M is the average lethal dose of the mixture. LD50a and LD50b are the average lethal doses of its components and pa and pb are portions of the components in a mixture (pa+pb=1). This formula determines the relationship between the average lethal doses of a mixture and its components in case the latter's action is additive. It was shown that the effect of the combined action of apomorphine with adrenalin was considerably in excess of the additive effect whereas the effect of the combined action of apomorphine with phenamine was significantly less than the additive effect. These results were discussed from the viewpoint of the importance of pyrocatechol-O-methyltransferase in the inactivation of pyrocatecholamines.


Internal Medicine Adrenalin Combine Action Apomorphine Lethal Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature Cited

  1. 1.
    M. L. Belen'kii, Elements of Quantitative Evaluation of the Pharmacological Effect [in Russian], Leningrad (1963), p. 81.Google Scholar
  2. 2.
    M. L. Belen'kii, M. A. Vitolinya, and É. A. Baumanis, Byull. Éksper. Biol. No. 4 (1966), p. 54.Google Scholar
  3. 3.
    J. Axelrod and M. J. Laroche, Science, Vol. 130 (1959), p. 800.PubMedGoogle Scholar
  4. 4.
    J. Axelrod, Biochem. Pharmacol., Suppl. to Vol. 12 (1963), p. 97.PubMedGoogle Scholar
  5. 5.
    Z. M. Bacq, L. Gosselin, A. Dresse et al., Science, Vol. 130 (1959), p. 453.PubMedGoogle Scholar
  6. 6.
    D. Bejrablaya J. H. Burn, and J. M. Walker, Brit. J. Pharmacol., Vol. 13 (1958), p. 461.Google Scholar
  7. 7.
    T. H. Burn, In book: A Ciba Foundation Symposium on Adrenergic Mechanisms, London (1960), p. 326.Google Scholar
  8. 8.
    D. J. Finney, Probit Analysis, Cambridge (1952), p. 131.Google Scholar
  9. 9.
    H. Green, R. W. Erickson, J. Pharmacol. Exp. Ther., Vol. 129 (1960), p. 237.PubMedGoogle Scholar
  10. 10.
    J. R. Grout, C. R. Creveling, and D. Calon, Fed. Proc., Vol. 19 (1960), p. 297.Google Scholar
  11. 11.
    J. R. McLean and M. McCartney, Proc. Soc. Exp. Biol., Vol. 107, New York (1961), p. 77.Google Scholar
  12. 12.
    J. R. Vane, In book: A Ciba Foundation Symposium on Adrenergic Mechanisms, London (1960), p. 356.Google Scholar

Copyright information

© Consultants Bureau 1966

Authors and Affiliations

  • M. L. Belen'kii
    • 1
  • M. A. Vitolinya
    • 1
  • R. O. Vitolinya
    • 1
  1. 1.Riga Medical InstituteRigaUSSR

Personalised recommendations